FindTrial
Sign In

The effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with EGFR mutation

The effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with EGFR mutation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098187
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

EFGR-TKI group:None
Observation group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age >= 18 years old; (2) Postoperative histopathological diagnosis of stage I invasive lung adenocarcinoma (8th edition TNM staging); (3) Presence of EGFR mutation (19 Del/L858R/G719X/L861Q/S768I/T790M, etc.); (4) Postoperative targeted therapy with EGFR-TKI (including gefitinib, icotinib, erlotinib, osimertinib, ametinib, vometinib, etc.); (5) Tumor removal by lobectomy/segmental/wedge resection and lymph node dissection; (6) No missing clinical and pathological data.

Exclusion criteria

Exclusion criteria: (1) Patients whose tumors were not completely removed; (2) Patients who started receiving adjuvant EGFR-TKI treatment more than 10 weeks after surgery; (3) Patients who had malignant tumors in the past 5 years; (4) Patients who received neoadjuvant therapy.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Secondary

MeasureTime frame
Relapse-free survival;—

Countries

China

Contacts

Public ContactJiandong Mei

West China Hospital, Sichuan University

jiandongmei4518@163.com+86 130 8800 4518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026